Didier Cupissol

14.0k total citations · 2 hit papers
160 papers, 8.9k citations indexed

About

Didier Cupissol is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Didier Cupissol has authored 160 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Oncology, 81 papers in Pulmonary and Respiratory Medicine and 36 papers in Otorhinolaryngology. Recurrent topics in Didier Cupissol's work include Sarcoma Diagnosis and Treatment (45 papers), Head and Neck Cancer Studies (36 papers) and Gastrointestinal Tumor Research and Treatment (19 papers). Didier Cupissol is often cited by papers focused on Sarcoma Diagnosis and Treatment (45 papers), Head and Neck Cancer Studies (36 papers) and Gastrointestinal Tumor Research and Treatment (19 papers). Didier Cupissol collaborates with scholars based in France, United States and Spain. Didier Cupissol's co-authors include Ricard Mesı́a, Éva Remenár, Frédéric Peyrade, Ricardo Hitt, D. De Raucourt, Jean‐Yves Blay, Sylvie Rottey, Marco Benasso, Carsten Bokemeyer and Fernando Rivera and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Didier Cupissol

155 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Didier Cupissol, Frédéric Peyrade et al. profile →
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

2007 1.2k citations M. Degardin, Didier Cupissol et al. profile →

Peers

Countries citing papers authored by Didier Cupissol

Since Specialization

Citations

This map shows the geographic impact of Didier Cupissol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Didier Cupissol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Didier Cupissol more than expected).

Fields of papers citing papers by Didier Cupissol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Didier Cupissol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Didier Cupissol. The network helps show where Didier Cupissol may publish in the future.

Co-authorship network of co-authors of Didier Cupissol

This figure shows the co-authorship network connecting the top 25 collaborators of Didier Cupissol. A scholar is included among the top collaborators of Didier Cupissol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Didier Cupissol. Didier Cupissol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08) 2023 ·SHILAP Revista de lepidopterología ·Jérôme Fayette, Caroline Even, Laurence Digue, Lionnel Geoffrois, Frédéric Rolland, Didier Cupissol, J. Guigay, Christophe Le Tourneau, (unknown), Sylvie Zanetta, Laurence Bozec, Christian Borel, (unknown), Valérie Costes‐Martineau, (unknown), (unknown), (unknown), Audrey Lardy-Cléaud, Sylvie Chabaud	6
2	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma 2020 ·Cancers ·(unknown), Christine Chevreau, (unknown), (unknown), Caroline Delmas, (unknown), Jean‐Yves Blay, Didier Cupissol, Emmanuelle Bompas, Antoîne Italiano, Nicolás Isambert, (unknown), Nicolas Penel, François Bertucci, Cécile Guillemet, (unknown), Stéphanie Foulon, Étienne Chatelut, Axel Le Cesne, Fabienne Thomas	3
3	970P MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) 2020 ·Annals of Oncology ·Caroline Even, Matthieu Texier, Christophe Le Tourneau, Rastislav Bahleda, Édith Borcoman, (unknown), (unknown), Aurélien Marabelle, Ingrid Breuskin, Didier Cupissol, Jérôme Fayette	2
4	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients 2019 ·British Journal of Clinical Pharmacology ·(unknown), Catherine Alix‐Panabières, Thierry Lafont, Ben Allal, R. Garrel, Laurence Digue, J. Guigay, Didier Cupissol, Jean‐Pierre Delord, Benjamin Lallemant, M. Alfonsi, Karine Aubry, Martine Mazel, François Bécher, (unknown), Étienne Chatelut, Fabienne Thomas	19
5	Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study 2019 ·International Journal of Cancer ·Sophie Piperno‐Neumann, Isabelle Ray‐Coquard, Bob‐Valéry Occéan, Valérie Laurence, Didier Cupissol, Christophe Perrin, Nicolas Penel, Emmanuelle Bompas, María Rios, Axel Le Cesne, Antoîne Italiano, Philippe Anract, Gonzague de Pinieux, Olivier Collard, François Bertucci, Florence Duffaud, Marie‐Cécile Le Deley, Jessy Delaye, Laurence Brugières, Jean‐Yves Blay	27
6	Methotrexate–Etoposide–Ifosfamide Compared with Doxorubicin–Cisplatin–Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18–25 Years 2019 ·Journal of Adolescent and Young Adult Oncology ·Perrine Marec‐Bérard, Valérie Laurence, Bob‐Valéry Occéan, Isabelle Ray‐Coquard, Claude Linassier, Nadège Corradini, Olivier Collard, L. Chaigneau, Didier Cupissol, Pierre Kerbrat, Esma Saâda-Bouzid, Corinne Delcambre, F. Gouin, Cécile Guillemet, Marta Jimenez, Cyril Lervat, Nathalie Gaspar, Marie‐Cécile Le Deley, Laurence Brugières, Sophie Piperno‐Neumann	12
7	Patients with primary localized high-grade sarcomas of the digestive tract excluding GIST : a retrospective study from the French sarcoma group. 2018 ·PubMed ·Alexandre de Nonneville, (unknown), Jean‐Yves Blay, Dominique Ranchère, (unknown), Antoîne Italiano, Sylvie Bonvalot, (unknown), Florence Duffaud, François Bertucci, Didier Cupissol, Nicolás Isambert, (unknown), Jean‐Michel Coindre, Sébastien Salas	1
8	Extensive limb-sparing surgery with reconstruction for sarcoma of the hand and wrist 2016 ·Orthopaedics & Traumatology Surgery & Research ·(unknown), Bertrand Coulet, Michel Chammas, Didier Cupissol, Cyril Lazerges	14
9	Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR 2016 ·Annals of Oncology ·J. Guigay, François Bidault, Jérôme Fayette, Caroline Even, Didier Cupissol, Frédéric Rolland, Frédéric Peyrade, Brigitte Laguerre, Christophe Le Tourneau, Sylvie Zanetta, L. Bozec Le Moal, Christian Borel, Laurence Digue, (unknown), (unknown), Valérie Costes, A. Aupérin, Laurence Faivre	1
10	The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment 2016 ·Annals of Oncology ·Jean‐Yves Blay, A. Le Cesne, Nicolas Penel, Emmanuelle Bompas, Christine Chevreau, Florence Duffaud, Marı́a Yolanda Rios, Pierre Kerbrat, Didier Cupissol, Philippe Anract, Jean‐Emmanuel Kurtz, Célèste Lebbé, François Bertucci, Sophie Piperno‐Neumann, (unknown), Nicolás Isambert, Pascale Dubray‐Longeras, Françoise Ducimetière, Jean‐Michel Coindre, Antoîne Italiano	8
11	A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck 2014 ·Annals of Oncology ·Tanguy Y. Seiwert, Jérôme Fayette, Didier Cupissol, J.M. del Campo, Paul M. Clément, Ricardo Hitt, M. Degardin, (unknown), (unknown), E. Ehrnrooth, Ezra E.W. Cohen	138
12	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) 2012 ·The Oncologist ·Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Bompas, Axel Le Cesne, Y Robin, Christine Chevreau, Jacques‐Olivier Bay, Guilhem Bousquet, Sophie Piperno‐Neumann, Nicolás Isambert, L. Lemaître, Charles Fournier, Eric Gauthier, Olivier Collard, Didier Cupissol, Stéphanie Clisant, Jean‐Yves Blay, Nicolas Penel, (unknown)	148
13	Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer 2012 ·Journal of Geriatric Oncology ·Stéphane Culine, C. Terret, Didier Cupissol, Gilles Romieu, Michel Fabbro, Damien Pouessel, Jean‐Pierre Droz, Sophie Gourgou	6
14	Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis 2010 ·British Journal of Cancer ·Armelle Dufresne, François Bertucci, Nicolas Penel, Axel Le Cesne, B. Bui, M. Tubiana-Hulin, Isabelle Ray‐Coquard, Didier Cupissol, Christine Chevreau, David Pérol, Anthony Gonçalvès, M. Carolina Jimenez, P P Bringuier, Jean‐Yves Blay	27
15	[Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report)]. 2006 ·PubMed ·Sylvie Négrier, Philippe Saïag, B. Guillot, O Vérola, Marie‐Françoise Avril, Christiane Bailly, Didier Cupissol, S. Dalac, A. Danino, Brigitte Dréno, Jean‐Jacques Grob, M.‐T. Leccia, C. Renaud-Vilmer, L. Bosquet	20
16	Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site 2004 ·Cancer ·Damien Pouessel, Stéphane Culine, Catherine Becht, Marc Ychou, Gilles Romieu, Michel Fabbro, Didier Cupissol, Frédéric Pinguet	36
17	Phase II Trial of Paclitaxel–Epirubicin in Patients With Recurrent Soft-Tissue Sarcoma 2002 ·American Journal of Clinical Oncology ·Xavier Pivot, Christine Chevreau, Didier Cupissol, Alain Lortholary, (unknown), Jean‐Christophe Eymard, Jacques‐Olivier Bay, Marie‐Christine Baranzelli, Monica Mita, (unknown), J. Savary, Antoine Thyss	14
18	Cutaneous melanoma 2001 ·British Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), Didier Cupissol, Jean Doré, Thierry Dorval, Jean-Rémy Garbay, C Vilmer	9
19	Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck 2000 ·Oncology ·Xavier Pivot, L. Cals, Didier Cupissol, Emmanuel Guardiola, X. Tchiknavorian, (unknown), (unknown), J. L. Wendling, (unknown), J. Savary, Antoine Thyss, M. Schneider	33
20	Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases 1998 ·The Lancet ·Jean‐Jacques Grob, Brigitte Dréno, Pauline de La Salmonière, M. Delaunay, Didier Cupissol, B. Guillot, P Souteyrand, B. Sassolas, Jean‐Pierre Césarini, (unknown), Catherine Lok, Claude Chastang, J J Bonerandi	274

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact